Unleashing the Potential of Tau Oligomer Inhibition™
To discover novel and differentiated small molecules and biomarkers focused on tau oligomer inhibition for the disease-modifying treatment of Alzheimer’s disease and other related neurodegenerative diseases
News & Upcoming Events
October 8, 2020: Oligomerix Relocates Headquarters to Accommodate Growth
May 8, 2020: Oligomerix Announces Appointment of Robert Foerster, Former Pfizer Executive, as Chief Financial Officer
Our recent publication of an in vivo proof-of-concept study showed that an oral small molecule drug for Alzheimer’s disease reduced the level of tau aggregates linked to neurotoxicity and disease progression.